U.S. corporations, including Pfizer and Alphabet, are increasingly issuing debt in euros, with reverse Yankee deals reaching a record €83 billion this year, a 35% increase from 2024. This surge, representing nearly 14% of overall euro corporate issuance, is driven by concerns over potential market disruptions stemming from trade policies, prompting these companies to diversify their funding sources.
Major U.S. corporations, including Pfizer Inc. and Alphabet Inc., are significantly increasing their debt issuance in euros, a trend highlighted by a record volume of over €83 billion in so-called reverse Yankee deals this year. This represents a substantial 35% year-over-year increase and accounts for nearly 14% of the total euro corporate issuance, according to Bloomberg data. The primary driver for this strategic shift is attributed to anxiety over potential U.S. market disruptions stemming from President Donald Trump’s tariff threats, compelling these companies to proactively seek alternative funding avenues and diversify their financing sources beyond the domestic market. This development suggests a growing strategic response by large U.S. firms to perceived trade policy risks and could indicate an early sign of a lasting change in the global corporate debt landscape, traditionally dominated by the U.S. market.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
Neutral
Sentiment Score
0.10
Ticker Sentiment
